TELA Bio Announces Second Quarter 2020 Financial Results

Rhea-AI Summary

TELA Bio reported a revenue of $3.5 million for Q2 2020, marking a 6% increase from Q2 2019. Despite this growth, procedural volume declines due to the COVID-19 pandemic impacted results. Gross profit rose to $2.1 million, representing 59% of revenue, up from 58% in the previous year. Operating expenses increased to $7.3 million, leading to a loss from operations of $5.2 million. The company completed a public offering, raising approximately $45 million. Due to COVID-19 uncertainty, TELA will not provide 2020 financial guidance.

Positive

• Revenue increased to $3.5 million, a 6% rise over Q2 2019.
• Gross profit margin improved to 59%, up from 58% in the prior year.
• Successfully completed a public offering raising approximately $45 million.

Negative

• Procedural volumes lower than expected due to COVID-19, affecting revenue.
• Operating expenses rose to $7.3 million, impacting overall loss.
• Net loss increased to $6.1 million compared to $5.3 million in Q2 2019.
• No financial guidance provided for 2020 due to COVID-19 uncertainty.

MALVERN, Pa., Aug. 12, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today reported financial results for the second quarter ended June 30, 2020. 

Recent Highlights

• Reported revenue of $3.5 million for the second quarter of 2020, increasing 6% over the second quarter of 2019
   
• Completed an underwritten public offering raising approximately $45.0 million in net proceeds
   
• Announced interim analysis from the BRAVO post-market study, showing low hernia recurrence and complication rates
   
• Proactively managed near-term expenses to control spending and maintain financial flexibility in response to the COVID-19 pandemic

"Our achievements in the second quarter demonstrate our team's resilience and flexibility to continue to support our patients and customers despite the many challenges associated with the pandemic," said Antony Koblish, co-founder, President and Chief Executive Officer of TELA Bio. "We were pleased by our performance in the quarter, highlighted by the positive interim results we saw with our BRAVO study, the innovative ways in which we have been able to engage our customers virtually, and the completion of a successful follow-on offering. While our results are encouraging, there continues to be uncertainty due to the rapidly evolving environment associated with COVID-19 and the recent outbreaks in certain regions of the country. Despite this, our team remains firmly resolute in achieving our operational objectives and executing our strategic initiatives to ensure that TELA Bio is well positioned for strong growth over the long-term."

Second Quarter 2020 Financial Results

Revenue was $3.5 million for the second quarter of 2020, an increase of 6% compared to the prior year period. Though our revenue increased over the prior year period, it was impacted by lower than expected procedural volumes as a result of hospitals and patients deferring elective procedures and other factors related to the COVID-19 pandemic.

Gross profit was $2.1 million for the second quarter of 2020, or 59% of revenue, compared to $1.9 million, or 58% of revenue, in the same period in 2019. The increase in gross margin was due to the decrease in the charge for excess and obsolete inventory adjustments as a percentage of revenue.

Operating expenses were $7.3 million in the second quarter of 2020, compared to $6.2 million in the same period in 2019. The increase was due to the expansion of our commercial organization and increased costs associated with operating as a public company, which was partially offset by the salary reductions, lower travel and consulting expenses resulting from the cost containment actions taken in response to the COVID-19 pandemic.

Loss from operations was $5.2 million in the second quarter of 2020, compared to a loss from operations of $4.3 million in the same period in 2019.

Net loss was $6.1 million in the second quarter of 2020, compared to a net loss of $5.3 million in the same period in 2019.

Total cash and cash equivalents at June 30, 2020 were $85.5 million.

Financial Outlook
There is considerable uncertainty and lack of visibility regarding the Company's near-term revenue growth prospects and product development plans due to the rapidly evolving environment resulting from the COVID-19 pandemic. The COVID-19 pandemic is a highly fluid situation and it is not currently possible for the Company to reasonably estimate the impact that it may have on financial and operating results.  Accordingly, TELA Bio will not be providing 2020 financial guidance. 

Conference Call and Webcast Details
The Company will host a live conference call and webcast to discuss these results and provide a corporate update on Wednesday, August 12, 2020, at 4:30 PM ET.

To participate in the call, please dial (855) 548-1219 (domestic) or (409) 217-8881 (international) and provide conference ID 6897439. The live webcast will be available on the Events & Presentations page of the investors section of TELA's website.

About TELA Bio, Inc.
TELA Bio, Inc. is a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. TELA's products are designed to improve on shortcomings of existing biologics and minimize long-term exposure to permanent synthetic material. TELA's portfolio is supported by quality, data-driven science and extensive pre-clinical research that has consistently demonstrated advantages over other commercially available products.

Caution Regarding Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA's management. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: the impact to our business of the ongoing COVID-19 pandemic, including but not limited to any impact on our ability to market our products, demand for our products due to deferral of procedures using our products or disruption in our supply chain, our ability to achieve or sustain profitability, our ability to gain market acceptance for our products and to accurately forecast and meet customer demand, our ability to compete successfully, our ability to enhance our product offerings, development and manufacturing problems, capacity constraints or delays in production of our products, maintenance of coverage and adequate reimbursement for procedures using our products, product defects or failures. These and other risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA assumes no obligation to updates to our forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.

TELA Bio Contact
Stuart Henderson
Vice President, Corporate Development and Investor Relations
TELA Bio, Inc.
484-320-2930

Investor Contact
Greg Chodaczek
347-620-7010 
ir@telabio.com

TELA Bio, Inc. Consolidated Balance Sheets (In thousands, except share and per share amounts) (Unaudited)
		June 30,				December 31,
		2020				2019
Assets
Current assets:
Cash and cash equivalents		$	85,471			$	45,302
Short-term investments			—				9,285
Accounts receivable, net			2,586				2,836
Inventory			4,572				4,603
Prepaid expenses and other assets			1,484				2,308
Total current assets			94,113				64,334
Property and equipment, net			678				677
Intangible assets, net			2,759				2,911
Total assets		$	97,550			$	67,922
Liabilities and stockholders' equity
Current liabilities:
Accounts payable		$	948			$	3,171
Accrued expenses and other current liabilities			2,675				3,542
Total current liabilities			3,623				6,713
Long‑term debt with related party			30,524				30,243
Other long‑term liabilities			—				4
Total liabilities			34,147				36,960
Stockholders' equity:
Preferred stock; $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding			—				—
Common stock; $0.001 par value: 200,000,000 shares authorized; 14,413,015 and 11,406,976 shares issued and 14,412,690 and 11,406,221 shares outstanding at June 30, 2020 and December 31, 2019, respectively			14				11
Additional paid-in capital			244,537				198,829
Accumulated other comprehensive income (loss)			12				(19	)
Accumulated deficit			(181,160	)			(167,859	)
Total stockholders' equity			63,403				30,962
Total liabilities and stockholders' equity		$	97,550			$	67,922

TELA Bio, Inc. Consolidated Statements of Operations and Comprehensive Loss (In thousands, except share and per share amounts) (Unaudited)
		Three months ended								Six months ended
		June 30,								June 30,
		2020				2019				2020				2019
Revenue		$	3,507			$	3,303			$	7,233			$	6,609
Cost of revenue (excluding amortization of intangible assets)			1,346				1,320				2,796				2,752
Amortization of intangible assets			76				76				152				152
Gross profit			2,085				1,907				4,285				3,705
Operating expenses:
Sales and marketing			4,123				3,947				9,392				7,942
General and administrative			2,149				1,205				4,667				2,529
Research and development			979				1,055				1,891				2,714
Total operating expenses			7,251				6,207				15,950				13,185
Loss from operations			(5,166	)			(4,300	)			(11,665	)			(9,480	)
Other (expense) income:
Interest expense			(884	)			(914	)			(1,763	)			(1,826	)
Change in fair value of preferred stock warrant liability			—				(74	)			—				(38	)
Other (expense) income			(31	)			27				127				117
Total other (expense) income			(915	)			(961	)			(1,636	)			(1,747	)
Net loss			(6,081	)			(5,261	)			(13,301	)			(11,227	)
Accretion of redeemable convertible preferred stock to redemption value			—				(2,762	)			—				(4,787	)
Net loss attributable to common stockholders		$	(6,081	)		$	(8,023	)		$	(13,301	)		$	(16,014	)
Net loss per common share, basic and diluted		$	(0.53	)		$	(27.06	)		$	(1.16	)		$	(54.06	)
Weighted average common shares outstanding, basic and diluted			11,443,122				296,467				11,424,952				296,231
Comprehensive loss:
Net loss		$	(6,081	)		$	(5,261	)		$	(13,301	)		$	(11,227	)
Foreign currency translation adjustment			4				1				31				(3	)
Comprehensive loss		$	(6,077	)		$	(5,260	)		$	(13,270	)		$	(11,230	)

 

FAQ

What were TELA Bio's Q2 2020 earnings results?

TELA Bio reported Q2 2020 revenue of $3.5 million, a 6% increase from Q2 2019, with a net loss of $6.1 million.

How did COVID-19 impact TELA Bio's financial results?

COVID-19 led to lower procedural volumes, affecting revenue growth and resulting in higher operating expenses.

What is TELA Bio's financial outlook for 2020?

TELA Bio has not provided financial guidance for 2020 due to the uncertainty caused by the COVID-19 pandemic.

What are the highlights from TELA Bio's second quarter earnings?

Highlights include a 6% revenue increase, improved gross profit margin, and completion of a $45 million public offering.